<SEC-DOCUMENT>0001193125-12-328903.txt : 20120801
<SEC-HEADER>0001193125-12-328903.hdr.sgml : 20120801
<ACCEPTANCE-DATETIME>20120801162957
ACCESSION NUMBER:		0001193125-12-328903
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20120801
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20120801
DATE AS OF CHANGE:		20120801

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			pSivida Corp.
		CENTRAL INDEX KEY:			0001314102
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				262774444
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51122
		FILM NUMBER:		121000430

	BUSINESS ADDRESS:	
		STREET 1:		400 PLEASANT STREET
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472
		BUSINESS PHONE:		617-926-5000

	MAIL ADDRESS:	
		STREET 1:		400 PLEASANT STREET
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	pSivida LTD
		DATE OF NAME CHANGE:	20050111
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d389611d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM&nbsp;8-K
</B></FONT></P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="4"><B>CURRENT REPORT </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d)&nbsp;of the </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Securities Exchange Act
of 1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of earliest event reported): August&nbsp;1, 2012 </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>PSIVIDA CORP. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact name of Registrant as specified in its charter) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>000-51122</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>26-2774444</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or Other Jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>of Incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>File Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(IRS Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>400 Pleasant Street </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Watertown, MA 02472 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of Principal Executive Offices) (Zip Code)
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(617) 926-5000 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(Registrant&#146;s Telephone Number, Including Area Code) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below
if the Form&nbsp;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule&nbsp;14d-2(b)&nbsp;under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule&nbsp;13e-4(c)&nbsp;under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;8.01.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Other Events. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">On
August&nbsp;1, 2012, pSivida Corp. (&#147;pSivida&#148;) issued a press release announcing that its partner Alimera Sciences, Inc. intends to resubmit its application for ILUVIEN<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> for diabetic macular edema to the U.S. Food and Drug Administration using data from its two previously completed pivotal Phase III clinical trials (FAME<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&#153;</SUP></FONT> Study). pSivida&#146;s press release is filed as Exhibit 99.1 to this Current Report on Form 8-K. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Financial Statements and Exhibits. </B></FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exhibits </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:25pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">pSivida Corp. 2008 Incentive Plan (incorporated by reference to Exhibit 10.41 to the Current Report on Form 8-K filed by pSivida on June 19, 2008).</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release of pSivida dated August 1, 2012.</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date: August&nbsp;1, 2012 </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">PSIVIDA CORP.</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Lori Freedman</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lori Freedman</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vice President Corporate Affairs, General Counsel and Secretary</FONT></TD></TR>
</TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT INDEX </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:25pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">pSivida Corp. 2008 Incentive Plan (incorporated by reference to Exhibit 10.41 to the Current Report on Form 8-K filed by pSivida on June 19, 2008).</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release of pSivida dated August 1, 2012.</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d389611dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px">


<IMG SRC="g389611g13c03.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>pSivida Corp. Reports Alimera&#146;s Intention to Resubmit Application to FDA for ILUVIEN<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> in DME Using Data from Completed Trials </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">WATERTOWN, MA, August&nbsp;1, 2012 - pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in developing sustained release, drug delivery
products for treatment of back-of-the-eye diseases, today reported that its licensee Alimera Sciences, Inc. has indicated its intention to resubmit its application for ILUVIEN<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> for diabetic macular edema (DME) to the U.S. Food and Drug Administration (FDA). Based on a recent meeting with the FDA, Alimera intends to use data from
Alimera&#146;s two previously completed pivotal Phase III clinical trials (FAME<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Study). pSivida expects the
resubmission to address the issues raised by the FDA in its November 2011 Complete Response Letter (CRL) and in its recent meeting with Alimera. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">pSivida anticipates the resubmission will focus on the population of patients with chronic DME considered insufficiently responsive to available therapies, the same indication for which regulatory
approval for ILUVIEN has been granted in various EU countries. Alimera has not reported an expected time for resubmission. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;We are very
pleased at this development in the U.S. in addition to the recent marketing authorizations in Austria, France, Germany, Portugal and the U.K.,&#148; said Dr.&nbsp;Paul Ashton, President and CEO of pSivida. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under a collaboration agreement with Alimera, pSivida granted Alimera an exclusive worldwide license to manufacture and sell ILUVIEN for the treatment
and prevention of eye diseases in humans other than uveitis. Alimera agreed to fund all development costs, pay pSivida a $25.0 million milestone payment upon FDA approval of ILUVIEN and 20% of any net profits, as defined, on sales of ILUVIEN by
Alimera. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In November 2011, the FDA stated in the CRL that it was unable to approve the ILUVIEN new drug application because it did not
provide sufficient data to support that ILUVIEN is safe and effective in the treatment of patients with DME. The FDA stated that the risks of adverse reactions shown for ILUVIEN in Alimera&#146;s clinical trials were significant and were not offset
by the benefits demonstrated by ILUVIEN in these clinical trials and indicated that Alimera would need conduct two additional clinical trials. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">pSivida is a US listed company with a primary listing on NASDAQ. It is also listed on the ASX and subject to the ASX&#146;s continuous disclosure rules
</FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About pSivida Corp. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px;"><FONT
STYLE="font-family:Times New Roman" SIZE="2">pSivida Corp., headquartered in Watertown, MA, develops tiny, sustained release, drug delivery products designed to deliver drugs at a controlled and steady rate for months or years. pSivida is currently
focused on treatment of chronic diseases of the back of the eye utilizing its core technology systems, Durasert&#153; and BioSilicon&#153;. The injectable, sustained release micro-insert ILUVIEN<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> for the treatment of chronic DME, licensed to Alimera Sciences, Inc., has received marketing authorization in Austria, France, Germany, Portugal and the U.K. and is
awaiting authorization in Italy and Spain. The FDA has cleared pSivida&#146;s Investigational New Drug application (IND) to treat posterior uveitis with the same micro-insert. An investigator-sponsored clinical trial is ongoing for an injectable,
bioerodible insert to treat glaucoma and ocular hypertension. pSivida&#146;s two FDA-approved products,
Retisert<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> and Vitrasert<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>, are implants that provide long-term, sustained drug delivery to treat two other chronic diseases of the retina. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995: Various statements made in this release are forward-looking, and are
inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect or believe may occur in the future are forward-looking statements. The following
are some of the factors that could cause actual results to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements: no assurance that Alimera will resubmit its
application or be able to demonstrate to the FDA that the benefits outweigh the risks of ILUVIEN for DME using data from the FAME Study, that additional clinical trials will not be required, that the population of chronic DME patients will be
acceptable to the FDA or that Alimera will be able to obtain regulatory approval for ILUVIEN for DME in the U.S.; ability of Alimera to consummate its pending financing; the timing and conditions for additional regulatory approvals are subject to
decisions by regulators; necessity to raise additional capital to finance Phase III uveitis trials as well as other working capital needs; ability to obtain additional capital; ability to initiate and complete clinical trials and obtain regulatory
approval of product candidates; adverse side effects; Alimera&#146;s ability to successfully obtain regulatory approval of and commercialize ILUVIEN for DME in the EU; actions with respect to regulatory approval of ILUVIEN for DME in the U.S.;
ability to attain profitability; exercise by Pfizer of the Latanoprost Product option; further impairment of intangible assets; fluctuations in operating results; decline in royalty revenues; ability to find partners to develop and market products;
termination of license agreements; competition; market acceptance of products and product candidates; reduction in use of products as a result of future guidelines, recommendations or studies; ability to protect intellectual property and avoid
infringement of others&#146; intellectual property; retention of key personnel; product liability; consolidation in the pharmaceutical and biotechnology industries; compliance with environmental laws; manufacturing risks; risks and costs of
international business operations; credit and financial market conditions; legislative or regulatory changes; volatility of stock price; possible dilution; possible influence by Pfizer; ability to pay any registration penalties; absence of
dividends; and other factors described in our filings with the Securities and Exchange Commission. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Our forward-looking statements speak
only as of the dates on which they are made. We do not undertake any obligation to publicly update or revise our forward-looking statements even if experience or future changes makes it clear that any projected results expressed or implied in such
statements will not be realized. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Released by: </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>US Public Relations</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Beverly Jedynak</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT
STYLE="font-family:Times New Roman" SIZE="2">President</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Martin E. Janis &amp; Company, Inc.</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tel: +1 (312) 943 1123</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>bjedynak@janispr.com</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>pSivida Corp.</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Brian Leedman</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vice President, Investor
Relations</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">pSivida Corp.</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tel: +61 (0)
41 228 1780</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>brianl@psivida.com</U></FONT></P></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g389611g13c03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g389611g13c03.jpg
M_]C_X0`817AI9@``24DJ``@``````````````/_L`!%$=6-K>0`!``0```!D
M``#_X000:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+P`\/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B`\
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835`@0V]R92`U+C`M8S`V,"`V,2XQ,S0W-S<L(#(P,3`O,#(O,3(M
M,3<Z,S(Z,#`@("`@("`@("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO
M+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<$U-/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C`O;6TO(B!X;6QN<SIS=%)E9CTB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87`O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(@>&UL
M;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O(B!X;6QN<SID
M8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B('AM<$U-.D1O
M8W5M96YT240](GAM<"YD:60Z135".#5",S!$0D)!,3%%,3@W.#=$-S$U0C4T
M.#%&13DB('AM<$U-.DEN<W1A;F-E240](GAM<"YI:60Z135".#5",D9$0D)!
M,3%%,3@W.#=$-S$U0C4T.#%&13DB('AM<#I#<F5A=&]R5&]O;#TB4%-C<FEP
M=#4N9&QL(%9E<G-I;VX@-2XR+C(B/B`\>&UP34TZ1&5R:79E9$9R;VT@<W12
M968Z:6YS=&%N8V5)1#TB=75I9#IF,#5B-S!A,"TW931E+31E8C<M.60T-RTP
M,S=F-#DS,V)D9C4B('-T4F5F.F1O8W5M96YT240](G5U:60Z.#EF.#@V,&,M
M86(S9BTT-3DX+3DT838M,&0P-34R969C9#=D(B\^(#QD8SIC<F5A=&]R/B`\
M<F1F.E-E<3X@/')D9CIL:3YN=F%L;&EA<'!A;CPO<F1F.FQI/B`\+W)D9CI3
M97$^(#PO9&,Z8W)E871O<CX@/&1C.G1I=&QE/B`\<F1F.D%L=#X@/')D9CIL
M:2!X;6PZ;&%N9STB>"UD969A=6QT(CY-:6-R;W-O9G0@5V]R9"`M(&5X.3DN
M9&]C>#PO<F1F.FQI/B`\+W)D9CI!;'0^(#PO9&,Z=&ET;&4^(#PO<F1F.D1E
M<V-R:7!T:6]N/B`\+W)D9CI21$8^(#PO>#IX;7!M971A/B`\/WAP86-K970@
M96YD/2)R(C\^_^T`2%!H;W1O<VAO<"`S+C``.$))300$```````/'`%:``,;
M)4<<`@```@`"`#A"24T$)0``````$/SA'XG(M\EX+S1B-`=8=^O_[@`.061O
M8F4`9,`````!_]L`A``!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`@("`@("`@("`@(#`P,#`P,#`P,#`0$!`0$!`0(!`0("
M`@$"`@,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P/_P``1"`!2`)\#`1$``A$!`Q$!_\0`PP`!```&`P$!````````
M``````$&!P@)"@(#!00+`0$``04!`0$`````````````!P$$!08(`@,)$```
M!@$#`@0"!`L$"@,````!`@,$!08'`!$((1(Q$Q0)02)A,C,5\%%Q@;'!0F(C
M)#21H34VT>%20V,6=A<X"K8W&1$``0(%`P(#!`4*`P0+`````0(#`!$$!08A
M,1)!!U%A$W&!(C+PD4(4%:&QT5)B<B,S)`C!DC7A@K)#4W.#-$1D="5%%A?_
MV@`,`P$``A$#$0`_`-^C2$-(10[-W(_#G'B$3FLIW)A"&=D4-$P*&[^T3QTP
M'=.&@6HG>NB]P=HJF`C<@C\ZA=9ZP8Q?LGJ?NECIUNK^TO9"!XK4=`/+<](Q
MUPNM#:V_4K'$I\!]KZHQ_P`%SIY"\D9YW`\5<)$:0K=QY+B]7M4'2,<D([`N
M^\I1M78M8"_,"'J'R^W[`ZDBK[<8YBC`J,TN4WU)F&&0`29;`ZK.NRI)$:\W
MD-QNCOI6=H^G/5:Q_AM%U51P=R%EDDGV6N2]D*[4_B.(#&T9&5^-0.;YA13E
MU(\CE0I1Z;E;D_/K3:Z_8TW-JRVE`;&@74+*UGSDD@:^Z,TQ;[@9+JJE9GN$
M\1+R&D5^A,9M(8A0/<,BRZQ=MUY>ZRKLQMNOS)E\AOX_B)K6WJ\O;,L(]C?^
MTQD4,!'VE'VF*@-FP-BB3SW*X#ML=TIYRO@`;"H)2F-X?'5B3-7*/L!+>/IU
MYBL-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$/A^'Y]``I02?E\/&'MVC%O[A_
MN.UCB/&$QS1?NZU<@K+'`ZBX9P;U$/0XEV`E:6NW)HG`3J+"4PL(_<JCH2]Y
M^U$-SRYVN[65^>O_`(A5A3&-LF:UC0NR_P"6V=IG92MD[?-I&BYAFE+CR!14
MTE7=P32F>B4_KK\M=$[JW`D(QL<*.'63>;MI=\C>2-EL[Z@R$@=4LE*.ET[#
MDQVU5,5:/@E1`J<'2HY4!1.JW(FF(AY+8H=ISEEK/\]LW;NC&)8>RRBY(3*2
M0"W3^:I3]1U6_P`6VA.IC6L=L-9D#OXO>5E5.HS$].?67DGP^J-DVI5"KT.O
M1E4IL#%UJN0S<C6-B(=FDR9MDDR@0NR:10\Q8P!\ZIQ,HH;<QC"81'7*=575
M=SJ%UM>ZMVJ</)2EF9)/TD!T&D2VTRU3MI980$-)&B1L(F+5KH=MH^D-(0TA
M#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$6E<WN5=6X;<<[QFRP`@]E8UNC
M"42MK*>6>UWV<!5K6X0H`)5#M0<E,Z>"3YDV+94_P#6XX'AU9G>44^-TA*4N
MGDZL?8921ZBAYRT3^T1&L9?DU+B5B>O-3(J1\*$G93BM$@^4]_"-1O@_AK(7
MN*<MW#W),Q*3B$S*O,G9RMYSJ$5+`D=I%/#L%?G)'JS2YDHR.2+L5LW`1(':
MCKM_N+?+5VHP1--8FT-.\/NU(C]H#YU#J42YJ)^94<V8'17'.,D55W-:EDJ+
MKQ/1,_A"?">P'0"-V=J:I8\BJA389DQ@X[^1JU1K48B5%%!JQ9&%-I'M4]@(
MSC(]H*BI_JD(03&'<>OY]*-;<W:BN>4I;@FXZXK7<@$D_M*.@W).FD=7+>I;
M?Z5,.(YG@A(ZD#H/("9.T3D.K2<_"+S7KO#2$-(0TA#2$-4F)RZP\X:K`R&\
MH:#43&T"0(:0AI"&FT/.'X>(:;F76'2<-(0VU28E/Z?5O%)B9'A#58J=(:0A
MI"-.G_V%>2+RY<D<:\98M^8*YAJJHW>U,TU=T'-]OZ8C&^J(38#+0E/12%/N
MW$OWB?;;?7<W]K>)HI,7J\N>D*JM?^[MDZE+;1'(CPYK)GY)$<B=_<E55Y)2
MXPU-3%(T'G$[`N.?+/QDG7WQEB]B7!37'/$$^6W[,B=DSS9WTX5X8@`L6F5-
MV[K5:9@<0[P05?MW[O8!V-Z@H_`-0Q_<?DBKOGQLR#.CMS8;D-O4<')9EUF"
M!.)<[*V86W#T5ZQ)^K<4N9W],$A`_(=/.+[<06[_`+R<A,LW$%O4UC%#)OC6
MD$*.[<7C]XLYM<ZGT[!<R"T21$I_'TY"@'B.^K999DXK@EJMBA_[E=E&KJ"1
MKP3(4[4_!(45*'ZV^HBYQ:[*RC.;I=P9V^VI^[,@'3DHDN+EU*BD`'P'G%X_
MCJ*=M(E5((2`=Y0V_OU28)(&I$5ZRZRG#5.229#4^4/$]!U_P]L1VUZ$S+0Z
M_36*$A,YRF.G6*7Y;R[4,+5)6X7%9X+,7;>-CXZ+;^LEIB4=^9Z:.C6HG2*H
MN<J1C")C%*0A1$1_'L&+8Q=<QNHM%F0E3Y0I:E*/%M#:/F6M71(_*8U_*,GM
M>(VM5UNRE>D%!"4I$UK6J92A(ZDRB@Z/)++TDD5Y!\3,JN8UP4%6KB1E8")<
M+('`#)G,R<$.LEW%$!V'J&^MN=[?V&G7Z-3E%I^\`D$!+R@DC<<DMR/M&D:<
MC/LCJ4A^FQNXJ8(FE14VDD'R*ICV1Q<<F<H0B*LC:N*>68V&:D,L]?QCV#G%
M6K<@=RJYF;4$5#D2(`F'Y@V`-_#7MCMY9:MT4])DUH<JEF2$GUVPI1T`Y%$A
M/ST@ON#D%.@NUN.7-NE2"5*26U<4C4F4]0/+6*]4W+-6R)CC_N92@?3<,>.D
MGC=@5OY$NH]BTEC.(51F(J>5*>H0\H";F`QC`)1$!`=:;>\8NE@ORL<O:4-5
MJ74(4J<VP%D2<"QNB1G/PC<K/DMOOM@3D%H+CM(II:PF4G"43F@@[+F)`?IC
MW,>6US?*7`6YW6IFGN)MHHZ5K5A2\B:B3$<KM_3OT>Q/L6,"('`.T/E.&K2]
MVQ%FNKUL14,U2&5!(=:F6UZ`S1,3EK*9W,75DN2[K:F;DZP[2K=05>DZ/XB0
M/UY=2-9=-HG/6*!G&6B(!OL'T@'7Z1#^W5"OBDB?$D[^44G)6FH_+/\`1M%N
M''?/LMG='*BDOAS(V'3XURO:,9L4,BL/0*7R/KPH`WR#5`%!#U51GO.'TJOS
M]W8/S:V+(L?9L*J1**REJ_O5(BH)945!I2YS:=G*3B2/B2-![XP-BO;EX35*
M<IGZ?[M5*8F[H'$I(`=1+4(5.8G%QP=?]8"']NM=Y#96Y^H^R,_*0D00(MSY
M;\BX7B3QSRIR,L-:EKA"8K@6T_(5R"=LF,M+(NIJ+A009.I#^315*M*%/NIT
M$I1#QVUL>'XQ5YEDU)C%"XAFLK5E`<<F4IXI*]>()((!U'6->RG(*;%[!47^
MK;+U/2I!*`0#(J"!(^/(B*Q4.UM[Y1J7>6;1=@TNE2KEM;,'1TE'+%M8X9G,
MH-'"B/\`"47:I/03.8GRB8HB'36&KZ-5NKWZ!9!53O*;)$^)*%%)4.HF1UZ1
MEJ&J36T3-8@&3[*7$@GX@%`*"3+0RG$U[:M^LC%W[>D0UY"TE/(;>PPD>L?G
M&^XG>'-^]P_F#97"QUP0S+9JXR$YM_+C:41K4XY`.H@`)MH4O3X"(Z_53M/;
MD6WM98Z5*4R52(=/FIQ163[?BC\Y\[KE7#N7=ZA2E$)JU('D&Y(`]FD;S?&I
M@AB'V]\-DC$_)"I\8*S-(%`.T?7KT5&=44$.NQU)%X8X_O#K\[[\C_[!W4J6
M'B?ZB]J0?W?7*!/V#2.WZ!W\#[<M/L":F+0%#]X,A4_\VL4Z]N02!2LD$.83
M/5;5$NG!C#N<Q5X;8%#"(;B)UB*#^7?4A?W$@IR&WJ$PR*)0`&P(=E(>XB(]
M[!R_!;@!JY][3,G<CB9$_EC(YKGH;"<3W$KWB0>1%*N,M'J^0_BZI8Y%BL)2
MJ`B]8P[UTU5%,X"0_EKHE'80V';8>FKJB92_6-,NZMJ=2"-M"0DCZB8L[D\Y
M3V]]]J7J(:6H3\4H)'Y1&!+@E9?=`]P3BYCO-DIR_J?&V$>EFXF.DJG@FH9`
MOF4'T)8)%E)W"R&G7\/6JE#@N06#*.CVQCF(R%=93N5``Z$SZA[5]M<MJ<?I
M[0]=GAQ40Y5.,M,)4V"EI`1R<6J?Q*6M0&H2E,A.(+PJL[DY_BU/>%W1JW-R
M4@%+"7772EP@N+4KBE*0/A"4@SD22(JOGVA^Y[Q"Q#?>1\%SUKW)1AA^O/[[
M;,/91XYTJCQMPIU<2&2LC"*M=*F59>'F_NI!4[=0`[1.781ZAK$8[7=K,UO5
M-BC^/KME5<'@RU44]8ZZIMQ9XH!0\"E2.1'+7E+:,G?J/N5B%GJ,E%\:KV*%
MM3CC#M*A"7&T?$OXD$J2KB#*6GG%U-\FYWEGQDXV<B\25E29.\/CO.+*B.'*
M0OGD=)0Z+Z0@2KJ`FBZ?1;E84AZ`*H$,)0$=BC8X._;L#S.\XEDCQ8:?IGZ`
MU`!DTH*("S+4)5]KKM%UFC-?FF)6G)<=9]9QM]BL2Q,36DIG($Z%29R]DXJ(
M/,95H4"2_';/\>]+_4M4J6#Q)%;KYB:;HCE(JY`/X&`I=PZ[!K&)[4A\C[C?
M[&ZUQ'_/*2/`D*`E,#8C0]8N_P#]34R)55CN[;QTD&^8TWD4S&AG'2KS4@2)
M*'E<)9]C8TI#^L>.*`8R+9`2"5917^?)LF1/<3#OT#7U/:&YD<::ZV9VH)^%
M`JDI*CN`"0`-?$RCPKNO;^)-5:;PVQ]I1IU*`!T.@\CO$\8M?8HC<"V>P<?U
M?(JQ&5OL345#/%UF-H1CEG;M-XUE3JN&SE!T@F)T#?(`;=NY3`(X3)J?)JG-
MF*'.@?Q8.4[*MA-GD`F13\*@4J,E#>,UCE1C;&%U%?A)'X<$/N)G.:7@"I7(
M*$P01J)2\(LIY$YKY<UK@IC/EGA*=;V&XXN>M<F9NQVK689VCE_$$5,O6]\@
MXTXLE'=<FHB#;>M;KL/+4%-%4![A[0UNE+BV$M]UZ_`KLE;5LJ"JFI'>9'H5
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M>'?5ID%1`IZ-`X^JM`T475?)/H1X&-%M^1W3),]J+?:G`G%K6UZ=0H`*]:J7
MNTE4OA#8D52.X(ZS$H\*N9N2+9AOW"<N9RFD[;'<7>0_(BN59JPB8N"6:8VQ
M1!DG(NO=\:U2]:\,1(Z?JUP.L8QP$PCMJ^SS`[90WC&K+CZ"R_=[72+<FI2P
M7ZA925R4=`0)R'G*+/#\SN-;:,ANE[6'FK7<JM"0D!$V64<DHF-SH1,Q2[C5
M"^YUS=PM2N3,IS@JG%RO9=C37"A8DQ=QZJ%^+6Z7(/'05\E@MEXF$I"4F'3!
M(JJ@E*(`!B[["(D+E<H>[78#?WL38L+EVJ*)WTWJA^K<:"W)#F$-L@!*4JFG
M4STUGN<7CK/<C,[*UDR[RS;J>L1S99:I4N!M)4>,U+4"HD2)Z:S\A;I[H^%?
M<(PYP/Y%R=WYBU[E5B*6J4=$9&JENPA5L6W&N1;RU5X&-PI=BILJ\0>.(>9*
MW!RQ=I>6NT54,4P'(7?:^T=\[;WSN/:F*.RN6B\MO.*96W5N/MN*]-<VW$O`
M$)*?E*3/GOI&N]RK/W`M&"U[M7=6KG;%-H2\A=.EI:4EQ$E(4@GY5:D'<1D,
MS9;N7T#Q)XAP/$!&C0$]=*[AR"R9F7(:D"XKF#<;'H$.:4O1X*PS,,TGGI7)
MB)I(E]08`*;9(1$!+&-BH</JLTN[F9FI<IJ=U];%.QRYU3P=7)HE()0DC=6F
MFT2%?*K+*?$[:UB?W=M]Q+"'GWB@(IVBTF:P%D!1'@)Q1H,7<J3B4RGOI4LK
MHW;WH(82XU^F]0.P"DD0]W\X$O,Z``[FVZ>.L^+IB\TE.`5!!.O]373`]R)3
MEJ>GA&O*MN4F?#-F-9<1Z%)[]G!,=!K[8X82Y#\LH7DIF[@-G'/V.KY997BI
M,9TX_<OZE0(2NA7&SP[JKIR]XI!)A>FS0U*76))$,1PFV<)M!(J<2+"*?F_X
MUB3N,6_N/8:"H8IOQ=-)5VY;JE\E)DY)ISB'$AQ`X'D.8*II&FMQ9,AR1O(Z
MW!;Q6L/N&V*J:6O0VE(0D_!-Q'+@HH4>>BN)"9%4CIJ-<X(!Y7>>?,.">E,1
MRCR!R:J/>7L`Z,M8',HT5`!_W:S1\0Q1^("`Z[N[:U+=3VTL+[1!:_#V1_E^
M%7O'$Z1R%F%*:3N->&%32HU[JO<5`@_48WK^.LVEE7VX,42,8;SAGN+,'%I^
M7U$7T32"P;E+XCWD?1AR#\=PU^=-U:78N[SOWJ2%,WV9/D:CD#[""#..X:51
MN_;!(:^=VT$"6NH9XGVZB441X%6A*"M\_4W"@)DML*V=,"&'M`TG!F54.D7?
M8OF*Q[M4WT^7J7>_MK<K+72WIM,S3.J2Y+7X73H?8%`?YHBCLE<44MRJ;6H\
M14M!2`>JVR5$?Y2?JC*YKE@3D)^$=,[ZQ)62O_K?(7_0UN_^/R.KVV_Z@Q_U
MR/\`C3&/N_\`I-5_Z=S_`(%1K:>T-[E7'KC;P3PSB;D@3(.)WD06Y25)MRV,
M;];*+DBK3%UGGQ)2MV2E5^P-B249+*NF+YBX!%9!1L!OF(<!UT]WM[8Y%D?<
M6NO&-JI*IMTLI<;]=IIUMQ#2!P4VXM)D4R4E8FDSZ1SGVC[BV''<'H[7?Q44
MSJ/6*%EIQQMU"G5*FE;:5)!"CQ*3)0E.+G>9/ND<9,]\8\U8(XPFRGR$S3FK
M'EFQ;1Z+1\+96;JC+W:.6@$I2:E;'4H2*B8:+*^,LLJHKOL38`V$3!J6$=K,
MHQK*Z#(<G-%06&WU2*EUURI840AI07)"$.*6I2B.(D-)SC:<P[E8Y?L:K;)C
M::NMN];3K8;;13O":G4\)J4M"4@)G,ZSETB["I8[SQQDX1\2:/5@EG=FPE5,
M71.6X*KE:2#Z5B8R"1"V1+(GE.!>I,I(3(F%`.XQ0[RCV@(ZQ-%78=F?<>^O
MWTMMT5T54JHW7E*0AMY:R6E**2)3!T"M/&+RY4>6XC@%EI['S<K;<FG35MM`
M*4MI"0EP)"@9ZC4C7PBN[?G%@HR)#.WMTBW)B[K1S^A6LKQFIN/>W<$18K(^
M8B;Y1[#F+N'0=8<]G,T2HA(H5)G+D*NG*3(:%)Y@R.^OC*,RCNYB"DA1^_#2
M9!I7@4S.Q'#<'20GXSC@\YQX-!NJ+!6[3SKL,",3'4*T"[?*"4>QND#IB@W_
M`(H_+N<P%#?KJJ>SF9*6E"_P]M!4)J55L22)ZDR63H-=-?"*.]V\2X'TDUSK
MTCQ0*9V:C+0:IEKYZ")"XWTNT5GCQFF4LE>=UAQD"5R);X:KN$3IOHR(DX)9
M*/059``';J*]@]B8D*?L`H]H;@&LYW'O=KN6>6FGMU0FJ9H&J.G<?21Q6MM8
MY'D93"?UC]<87`;1<Z#";L_<6%4[U:NK?0T1JE"T'BF0GJ9["*P<1H[S.+N*
MXN58"!%JM(,G\=)-#`"B#B7ETW#5XR=)E$R2Z*@E,0Y=C%'J&PZU3NL^EWN/
M<ZFC=!0:N:5H4"/D1)25#28(W!TUC9^US"T=O[:Q4H(<]`\D+!&A6HD*21MK
ML1J(P/W3(7(3VK;'R0X680QQ=\@5?D:\)=_;RDZ_$/IB#Q;<<K6%&L7JAV.0
M0261A(>@RTH,NR%8Q4]DB&,`%7.8LR4=MQGNY26K-\@JJ>EJK<"S>$*6$K>;
MIT%QIY*205J=XAI13,F?[.L7U5;D/;!^Y8C9*9]^FKU!=J4A/)#+CRBEUM1V
M2&RKF.4A]<XSB\&>*T!PYXX4'#$4Y^^+$T16LN3[>J(JO[SE6S*A)7BUR#LX
MBL[,]EE#)(&.(F*T12+X@.H'SS+JC.,EJ+ZL!%*I7"G;V2U3MCBTA(&@`2)F
M7VB3$T87C3&(8[3VAL<JD#D^O=3CR_B<6HG4_%-(/ZH`Z1BR]O[$EGR3QI]V
M[$X,'\!-94Y4\NZS6UYQ@\BD5U;=5RQ$+)(G?(H`YB5WK@O\=/N3$@"(".VI
M>[BWZBM>589>TN-NM45FMSBRA05+TG%%22`20M*=TD3F8BW!;-5W+&\LM:D+
M9=K+K7H1S24SYH"4*$P`4J)^8&4?1P<]R'`7%+B[A[C+RZ897X[YJP146N,[
M76KAAO)LI&RJU97<LFT]5;)4ZQ8(2<AI9H5-5-1-8.IAVW+VG-\>X/;B_P"8
MYA7Y3B"Z*X8_<'U5#:VZEA)`6)E*T+6E25)5H1+<1],)[@6+$L7H\8RA%717
MJA;]%;:Z=Y0)23)25H0I!20)B1,I^&L2%[F_N)8:Y3<%^1&(.*%?ROG:=L=-
M9*VJ=@\1Y'K].Q]4XFRP<M+SM@L%MK<$W=/U/0IM6<<R*X>.7"X"!`3(8P7_
M`&K[=W;$.X5MO67NT5OI&'E!(74,N...%M02A*6W%'KR*U22`#K/2++N-GUJ
MRC"KA:,5:JZVL<;;Y%+3B$-I]1*BI2EI`)D)!*9DDS,AK$O^Y!7(X*[[2=JS
MW2<@W?A938!@7DG6:K"6J=CF<B\Q=3TZ2_O%;JVTRO%M'S5R4W<3Y2%62#YU
M`(;[]LGN=1F--87J1C.GU'[BXZMM!EZ[GK>FMPA`5P(D9^^/CW)8'H8O47EJ
MH?PQF7WQ#:5K$_13Z7-"!R(G.>WAN91]1<C?^N"*1>W$6'S")`#L#B]F@RP_
M+L!-QQ]WBKM^]OO].AM_]RB4S57U7"<]*ZG`^'[0_B[>?AXP_$?[?5`_TE/I
M_P"4J-">A'IZ^P:10+CLTX@__HWF*X8LPYD6I<&%?;HS"2TQEQQQE".I=CJJ
M4BDKDXE#J5C;+V7_`)4FX%)T0D:U214>N2N!:MQ\P!-G\C5EH[76^V7.NHG<
M\&5-<%-/L<TK(_@+=<0KAS2L@EU1(`(*E"4HP5A;Q@]Q*NLMM%5M80,;>#B7
M&7@A3?+DXEIM8YE*D<AZ8`4=>*3I%EWOI8+>XJ]P2:R$BT.C6N0-,K=]C7)2
M[-SV"OLVU-M[0#[;"NDO%-')R]1V>E'P$-2K_;;DC5Z[:)M*]:NW5*VB.H;<
M5S;,O#50)\HT?O?87+5W#5<I28KJ=+B3TYHDEQ.G70$#?6,Z'L.YV89%XGRN
M$)5VFI8\'V1\Q;,%E`$[B@75PYG89=-,QA,H@UF5I!H80^4@%3`?K!KG+^Y#
M&U67.!?VM*2X,H5R&P?:^!7L,@E0]\3]V8O+=QQ06E>K]$M22/%I9*DGSW*3
M+P$3M:*C+X6R^_1BA.U4@YT)^KNA`P)KQ*[@[F/#IMYB`)"9LL`=![3`.I"M
M-UHLVPI**F2UN,>B\.H6-"=9R4)!:/&(QNELJL1RY1IY@-O>JT?UD;A.G0@E
M*AOH=HRO8\O45D&L,)^-.4BBB1$I)EW!YL=(E+_,M%2]#`4IPW3,(;*)B!@U
MRE?;+56&YKMM2-E'TU=%H^R1X:;CH9QTO8[U2WNVHN#!W2.8ZH5U!'@3J/*4
M>W:HA2P5>R0"*Y&JT]7IJ&1<J$,HFW5E(URQ(NHF00.HFB9?N,`"`B`;!K&T
MC_H/MU(!(0XE1'4A*@2!YR&D9"N9544;U,"`5MJ03X%8(2?9KK%HWM^\5)?A
MQQ(Q7QMM=HA,@RN/0L_J;-%0SF.BI`\_:YJQIBTCI55VZ;"V2E02-W''N,41
M#H.VMQ[B9<C-\PJ\F8972M5/IR;*^1'!"4S*@!H>,Y2\HU/`L5<Q'%Z?'7W4
M5/W=3GQ@``A:U+D`9F8).LXO11;MVXB+=!!N)OK^0@DB)P^`&%,A1$`UI!FH
MS65';<G3R'D>HC<@VVGY`$Z]--]_H8[P';;Z/#5):2CW'6*2)A[CH('-\3'1
M3.8?'Q,8HB(]=53-(DDD#VF/"FFU_.E),^H$"I)$,!B(HD,'[1$DRF_)W`4!
MVT45+'%1)$$M-),TI2#Y`#\T<QZ^(>/C]/C_`*=4E+1.@\-(]G42,Y>TP_N_
M)M^CP^.A$P`?E\(#33I]-#Y1$!$-P#H`[[AT\1^/AOOH9G<ZQ1("92Z;>40\
M`V^&G$'?7Z'P]L5&FHWT_)$KVVXU^CQ:4Q8W2S=LX?LH=B@RCWDI)2DK(J"F
MQBHR+C&[E](OG1BCVIIIF$"E$P[%`1!Q$I=/I[XI(==3].D2JPRK3IF9BJ[(
MQEF@Y"8.[3@T[M2INOM)1RQ9JOWC./?S$>FQ4>),&ZBHI=Y3BFF8P`(%':J9
MI^4D'R,OS112$KEZ@"I;3`,>:SS;2%VGJX"&ODQ!F,N9";K>-K9(5]Z1`YDE
MGD>\90_E2#,#)#LLB4Y%`#<@F#KJBQZA!43]>\_&"$);$D`)GX`#7Q]L?6\S
M;CE`E:*UD)*PJW6#>6"M,JU7)NQ.YF'8+MVLBLFTCX]<Z(,5G1"K$7!,R8@(
M&`!`0U0I!W\OR14@&8(T/3I'CFS5B9%),RZ<BS?GL9:F,"YHDVC9T[&>(//-
M(H]?-#_>8+OXI,56QRIF37#ZAAU]"M9^T?K_`">^/GZ#,YE""?W1^B/80S+4
M57J,4[C+O#R+QI)N(>-GZ)98EQ/C#,59%]'5\KR.(E*2Q&*)CD9IF\]4"CV$
M-L.WSXZ2CWP$I>4OS_IC'E[Q/#)YRVXP+RU+B?O++^#7CS(-";-TNY_/Q@,S
M(W6FM^TIE55IJ&1*X:IA]H^9(E`/FU-/8S/DX+F*$UJ^-FKDAETG9!G-MT^2
M%:*_948B_NUAYRS&5*I4@W6C)=:\52'Q(]X$Y>($:P7MW\H)GB3GBJ9,;D>.
M:LZ`]7R57T0.567IDBX2^\@(V,9,#2T&Y0(\:E-L/J$.P>AS!KL+NOAE-G6+
MO6YLH-<VCUJ=6A`7K*9Z!<RE4O$1`G;6_O8[<VZL)46%`I<0=#(GXB?W?F`]
MT;IU_I]1Y$T"LWNB2\?+'>1*$W3+&S4(=A-PTDD1T+)14FXE2<B`;=WS-W!1
M`P`/>&N$<8R*OPF\/4%S;6A@N<7VR)%"DZ!8\QT/41TQE..TV56Y#U&I/WQ"
M>32ALL$3XGZ::Q;/0I>T8SL"Q4$UV#I$_I9F%>E.1%P1,P[I.4O$IPVW35+U
M#?<HB`ZE;(:*UY5;TNDH+<B4.)/Q)G^8>(B,K)57/'*WAQ4VZ#Q6@B:3+0S!
MW\CTB^^I9&K]K;I`FM]WR(E`%8YZ8A%`.)=Q!!8QBINB?B$OS?C`-01=,?N%
MI<)<!<9GHM(^'R)_5/C$T6R]T=T;Y`A#V@*3^;S$3_\`$`Z`/38/R^&L'Q3+
MB#-4I>[K[8S6AUDD@;>40UZA$=OP_+X!^72*$@:1#2/6D-(I#2$-(0TA#2$4
MKRM4;#9V-0D:H,4I8*->8>ZL(Z<<N&,9,E8,Y.->1:\@U;/%H]5=G*G,BMY*
MI2JD+W%$HCI"/,.GERU2L,TFZQ3:=6FRLDK/.DK&:X33YNYAW\<U8P:!J]%H
MQ#CU+PBBKL5>\$DS)E*/>.R$>!2&&:,=TZMT-M2:/8DJE#LZ]'6(M^>PJ$DT
MC4@;1[UW$K5-ZZ9+J-R$,ND154._N[#"`AI".G&N'K#2)W'+]_(Q#]"K8\OE
M?FE6?J4C+6&Z7*,MI_NUNND)C1#4R*Z0'4.500`@B7J.R$=>98F38W3#D[2J
M_$OK.[R.[=R7KA7CFTLE'XYM+!$):89,GZS0Z+$PHM5E$E")J"4HAL.D(^N=
MA,LW6=I4O+5&IUYICV8E+>T9(79Q,/K)-A69F$AX,JY*TQ;0S!9>7$SAT?SC
M$*4.U(W4=(1<,']@AU`?Q#\!U0Z"?E+Z_IOTAKN(UB_=!]L60J-JL?*+CS73
MOJC..7,]EG'4&T%1U6)=41<2EYJ\8U*8Z]>DU3&6DFJ11.S7$RY`%(Y@2ZY[
M,]XFWZ5G"\I=":E"`W3ON'X%B4@TX?UD[(4=#L==8@O-NW_W>M5D-D1-I2^3
MK8&J3U6!U&\TCK%+/;UY[V/C*LG0[BG(6K"<P\!RI'-E/.F*,]=&`SJ9JY%3
M`FNP=''O>,!,4JIOXB8E4W`^;[I=KZ;+4F[6LH9R%*-Y?PWP)R2N7RJZ!8GI
M*<?7$<H<M'])5<E6V>GBB?5/74STC9;BU,3<A*M&72HS<59(M\W(=E9H%=,S
MQN)R]WHWQ!#S47"`CLHU=$*HF;H(`.N4&*S(<1K54-0AQIY)(4TXDE)\9$R!
M'4*3N(E&JMMHO[0?FE2R/A6C57^]Y^,XEH^()J,,(L7#61;E[A*8Q@:.0``#
M83)J"=(3;?B/K8$YC2U2?ZI"D$[R^)/N$MHU\XK4,+`84');#Y3[SU,3?#L;
MA'`5,!?D*4`(!17(ND!?C]H=0NW36(K'[-4?$D(F>LI1EJ5BZLC@LJX^$YQ/
MS)*>4*!G*X$+MM\WD@;?XCLF41_1K!/+H$*DV"3&;916R_B*CW44CIA_$.8Y
MNO4P@._4!`W0=@$=6*U)4?A$A%TE,A\6ICM$P;["/7?PV'Q'\WT:\Q[B.D(:
M0AI"&D(:0AI"'Z_'].D(:0AI"([B'X?3O^D-(1#2$-(0$I3%,4Q0,4P"40'P
M$!`0,40^(&#H(?$->5?+Q$]NFX'B/9"4_/7:,37*#VK,:Y3DI&^85=1^)[X^
M46>24$1F<V/[*^5,951=2.:!YU8?N%!$3K,R'0.8=S(=PB;4U8;WIO5A81;K
MV%U]K0.*5$\7D)VD"?GEX*^N-*O&&458M510GT'SN")H4?,#5/M$8X87&_,/
MAI9%))O#W2FD\SRW<Y6@&R4:?12,/;]XF9%>Q+IL8I0$`>))+%`?`HZEBJN_
M;_N%2AIQ=.^]Q^%"SPJ$3&LB9;>"20?.-::I+]87`4AQ"1_T?Q(/M\O=/WQD
M/Q7[DT^Y;-6F2J)'RJY2E(XEZD]^ZW*A@VW45A9+U#8JH@7J!%TR_0&HNN_:
M)E!+MEJ_A)T0X-QX!0E+WZQM-+E+BI(JFID=1UB[Z$YI8>F4R&,A;8Y0X`(I
M.H9NL!1$-Q#S&C]<@[?CV#6C/]OLAIU:^BKV+'Z(S3=ZHU[%SZHG^/Y"T^<.
M5"N1%KG'"G0A&D24@=WP[S&7,8A1^(B7IK&/XS74B>54MIH>:P?J'6+ENN:<
M_EH4?"*CQ;RV3/:L\C4:RR$.XJ:RI7TJH40^J)"`1NVW`?CW#]&L.\W1TYXM
MK]9WQ&@$7*5.+$^/`>!WB;4DRI$`I1.8?VCG-W'.;XF..W41#5J3,SCZ`2CG
MJD5AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI".M;[%?[#Z@_P!3]A^U]O\`
M\/\`VM5;_FIW_P!WYHHO^7%A>8/ZQ?\`\,_MQ_S#_F'ZP?U/[_Z]2-9/Y8_U
MS8?R_E]WE&`J]S_W/?[6_OB2J+_B#;_Q)^U)_1_4^/U?P\-7UQ^7_P":]_\`
MC'PIOF_\/[MHR`T__#B?Y+\`_P`E_P"'^!?#]S]6HUK]Q_._[3??I&Q,[?9]
FT38'@'ZO#\VK2/K#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA'_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
